MedTrace Logo

Pharmacokinetics and Pharmacodynamics of High Dose Ceftriaxone in Patients With Sepsis

NCT07245966 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2025-11-24

No results posted yet for this study

Summary

As the general treatment method for infectious diseases is to prescribe antibiotics which can be complete at the empirical treatment with the control of the sources of infection, the types of antibiotics that contain the broad spectrum and the proper dose to reduce the severity of infection play an important role. Especially, patients with sepsis should receive antibiotics within 1 hours after the diagnosis since the delay of 1 hour will decrease the rate of survival by 7.6 percent. Ceftriaxone is considered to be Cephalosporin, the antibiotics in the group of β-lactams antibiotic which kills bacteria by preventing the creation of significant cell walls. Ceftriaxone is soluble and can be excreted by the kidney. It is a β-lactams broad spectrum which can kill bacteria broadly including various types of gram-positive and gram-negative. The effectiveness of Ceftriaxone is in accord with the percentage of time that the level of the drug is beyond the minimum inhibitory concentration. According to the research in animals conducted by Craig WA and others, the drug effect to prevent the bacteria growth will occur when the %ft\>MIC is more than at least 40%. The rate of prevention will reach the maximal bactericidal effect when the %ft\>MIC is equal to 60 to 70%. At the moment, physicians prefer the 60 to 70% of %ft\>MIC in the group of Cephalosporins drugs as the main pharmacodynamics to cope with infections.

Conditions

Sponsors & Collaborators

  • Prince of Songkla University

    lead OTHER

Principal Investigators

  • Sarunyou Chusri, M.D., Ph.D. · Prince of Songkla University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-01
Primary Completion
2025-01-31
Completion
2025-02-28

Countries

  • Thailand

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07245966 on ClinicalTrials.gov